SABCS 2023 highlights: PARSIFAL-LONG, MONARCH 3, KATHERINE
Автор: VJOncology
Загружено: 2024-03-08
Просмотров: 87
Описание:
Antonio Llombart-Cussac, MD, PhD, Hospital Arnau de Vilanova, Valencia, Spain, shares his highlights from SABCS 2023, emphasizing significant advancements in CDK4/6 inhibitors, citing studies like PARSIFAL-LONG, an a 5-year extended follow-up of the Phase II PARSIFAL trial (NCT02491983), and Phase III MONARCH 3 (NCT02246621) that demonstrate improved survival in first-line treatment. He discusses emerging insights into early resistance mechanisms to CDK4/6 inhibitors, suggesting potential for alternative treatment approaches. Regarding HER2-positive breast cancer, he mentions promising data from trials like the Phase III KATHERINE trial (NCT01772472) which suggests a survival benefit with TDM1 versus trastuzumab. Dr Llombart-Cussac also notes advancements in local treatment strategies, particularly in sentinel lymph node evaluation and radiotherapy, which aim to reduce treatment-related toxicities and improve patient outcomes in both metastatic and early-stage breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
